Ke Keʻena ʻOihana Lapaʻau Lapaʻau, Halemai Kanaka o Guangxi Zhuang Autonomous Region, Nanning, Kina
Ke Keʻena ʻOihana Lapaʻau Lapaʻau, Halemai Hoʻohui o Shandong University of Traditional Chinese Medicine, Jinan
Huang Huayi, Kula o ka Laboratory Medicine, Youjiang National Medical University, Baise, Guangxi, 533000, Mindray North America, Mahwah, New Jersey, 07430, USA.
Ke Keʻena ʻOihana Lapaʻau Lapaʻau, Halemai Kanaka o Guangxi Zhuang Autonomous Region, Nanning, Kina
Ke Keʻena ʻOihana Lapaʻau Lapaʻau, Halemai Hoʻohui o Shandong University of Traditional Chinese Medicine, Jinan
Huang Huayi, Kula o ka Laboratory Medicine, Youjiang National Medical University, Baise, Guangxi, 533000, Mindray North America, Mahwah, New Jersey, 07430, USA.
E hoʻohana i ka loulou ma lalo nei e kaʻana like i ka mana kikokikona piha o kēia ʻatikala me kāu mau hoaaloha a me nā hoa hana.Aʻo hou mai.
I mea e hoʻomaopopo maikaʻi ai i nā loli pathological o COVID-19, kūpono ia i ka hoʻokele lapaʻau o ka maʻi a me ka hoʻomākaukau ʻana no ka nalu o nā maʻi maʻi like i ka wā e hiki mai ana.
ʻO nā ʻāpana hematological o 52 mau mea maʻi COVID-19 i hoʻokomo ʻia i nā halemai i koho ʻia i nānā ʻia.Ua kālailai ʻia ka ʻikepili me ka hoʻohana ʻana i ka polokalamu helu SPSS.
Ma mua o ka hoʻomaʻamaʻa ʻana, ʻoi aku ka haʻahaʻa o nā ʻāpana T cell, nā lymphocytes holoʻokoʻa, ka laulā o ke koko ʻulaʻula (RDW), nā eosinophils a me nā basophils i haʻahaʻa loa ma mua o ka mālama ʻana, ʻoiai nā hōʻailona mumū o nā neutrophils, neutrophils a me nā lymphocytes ʻO ka ratio (NLR) a me C β-reactive protein ( ʻO nā pae CRP) a me nā keʻena koko ʻulaʻula (RBC) a me ka hemoglobin i emi nui ma hope o ka mālama ʻana.ʻO nā subsets cell T, nā lymphocytes a me nā basophils o nā maʻi maʻi koʻikoʻi a ʻoi loa ka haʻahaʻa ma mua o ka poʻe maʻi maʻi.ʻO Neutrophils, NLR, eosinophils, procalcitonin (PCT) a me CRP he kiʻekiʻe loa i nā maʻi koʻikoʻi a me ka maʻi koʻikoʻi ma mua o nā maʻi maʻi.ʻO ka CD3+, CD8+, nā lymphocytes a pau, nā platelets, a me nā basophils o nā maʻi ma mua o 50 mau makahiki he haʻahaʻa ma mua o ka poʻe ma lalo o 50 mau makahiki, ʻoiai nā neutrophils, NLR, CRP, RDW i nā maʻi ma mua o 50 mau makahiki ʻoi aku ka kiʻekiʻe ma mua o ka poʻe ma lalo o 50 mau makahiki.I nā poʻe maʻi koʻikoʻi a me ka maʻi koʻikoʻi, aia kahi pilina maikaʻi ma waena o ka prothrombin time (PT), alanine aminotransferase (ALT) a me aspartate aminotransferase (AST).
ʻO nā subsets cell T, helu lymphocyte, RDW, neutrophils, eosinophils, NLR, CRP, PT, ALT a me AST he mau hōʻailona koʻikoʻi i ka hoʻokele, ʻoi aku ka nui o nā maʻi maʻi maʻi me COVID-19.
ʻO ka maʻi maʻi 2019 Coronavirus (COVID-19) i hoʻokumu ʻia e kahi ʻano coronavirus hou i puka mai i Dekemaba 2019 a laha wikiwiki a puni ka honua.1-3 I ka hoʻomaka ʻana o ka maʻi maʻi, ʻo ka nānā ʻana i ka maʻi ma nā hōʻike a me ka epidemiology, i hui pū ʻia me ka tomography computed i nā maʻi kiʻi 4 a me 5, a laila ʻike ʻia me nā hopena amplification nucleotide maikaʻi.Eia nō naʻe, ua ʻike ʻia nā ʻeha pathological like ʻole ma nā ʻāpana like ʻole.6-9 ʻOi aku ka nui o nā hōʻike hōʻike e ʻoi aku ka paʻakikī o nā loli pathophysiological o COVID-19.Hoʻopilikia ka maʻi maʻi i ka nui o nā kino a me ka ʻōnaehana pale.Ua ʻike ʻia ka piʻi ʻana o nā cytokines serum a me alveolar a me nā protein pane inflammatory 7, 10-12, a ua ʻike ʻia nā lymphopenia a me nā ʻāpana T cell abnormal i nā maʻi maʻi maʻi.13, 14 Ua hōʻike ʻia ua lilo ka ratio o nā neutrophils i nā lymphocytes i mea hōʻailona kūpono no ka hoʻokaʻawale ʻana i nā nodules thyroid malignant a benign i ka hana lapaʻau.15 Hiki i ka NLR ke kōkua i ka hoʻokaʻawale ʻana i nā maʻi me ka ulcerative colitis mai nā mana olakino.16 He kuleana hoʻi ia i ka thyroiditis a pili pū me ka maʻi diabetes type 2.ʻO 17, 18 RDW kahi hōʻailona o ka erythrocytosis.Ua ʻike nā haʻawina he kōkua ia i ka hoʻokaʻawale ʻana i nā nodules thyroid, ka ʻike ʻana i ka maʻi rheumatoid arthritis, ka maʻi lumbar disc, a me ka thyroiditis.19-21 ʻO ka CRP kahi mea wānana ākea o ka mumū a ua aʻo ʻia i nā hihia he nui.22 Ua ʻike ʻia i kēia manawa ua komo pū ʻo NLR, RDW a me CRP i COVID-19 a he hana koʻikoʻi i ka ʻike a me ka wānana o ka maʻi.11, 14, 23-25 No laila, he mea nui nā hopena o nā hoʻokolohua laboratory no ka loiloi ʻana i ke kūlana o ka mea maʻi a me ka hoʻoholo ʻana i ka mālama ʻana.Ua hoʻopaʻa hou mākou i nā ʻāpana o nā mea maʻi 52 COVID-19 i hoʻopaʻa ʻia i nā haukapila i koho ʻia ma Kina Hema e like me kā lākou ma mua a ma hope o ka mālama ʻana, ka paʻakikī, a me ka makahiki, e hoʻomaopopo hou i nā loli pathological o ka maʻi a kōkua i ka hoʻokele olakino e hiki mai ana. o COVID-19 .
Ua hana kēia noiʻi i kahi loiloi retrospective o 52 mau maʻi COVID-19 i hoʻokomo ʻia i ka haukapila i koho ʻia ʻo Nanning Fourth Hospital mai Ianuali 24, 2020 a hiki i Malaki 2, 2020. Ma waena o lākou, he 45 ka maʻi maʻi a he 5 ka maʻi koʻikoʻi.No ka laʻana, ʻo ka makahiki mai 3 mahina a 85 mau makahiki.Ma ke ʻano o ke kāne, he 27 kāne a he 25 wahine.Loaʻa i ka mea maʻi nā hōʻailona e like me ke kuni, ka ʻū maloʻo, ka luhi, ke poʻo, ka hanu, ka ihu o ka ihu, ka ʻeha ʻāʻī, ka ʻeha ʻiʻo, ka maʻi maʻi, a me ka myalgia.Ua hōʻike ʻia ka helu helu helu ʻana i ka ʻāʻī a i ʻole ke aniani lepo, e hōʻike ana i ka maʻi pneumonia.E hōʻoia e like me ka 7th edition of the Chinese COVID-19 Diagnosis and Treatment Guidelines.Hoʻopaʻa ʻia e ka ʻike qPCR manawa maoli o nā nucleotides viral.Wahi a nā pae hoʻohālikelike, ua hoʻokaʻawale ʻia nā maʻi i nā pūʻulu haʻahaʻa, koʻikoʻi, a koʻikoʻi.I nā hihia haʻahaʻa, hoʻomohala ka mea maʻi i ke kuni a me ka maʻi hanu, a hōʻike nā ʻike kiʻi i nā ʻano pneumonia.Inā hoʻokō ka mea maʻi i kekahi o kēia mau pae, ua koʻikoʻi ka ʻike: (a) pilikia hanu (ka hanu hanu ≥30 hanu / min);(b) hoʻomaha manamana lima koko oxygen saturation ≤93%;(c) puʻe oxygen arterial (PO2) )/Hapana hoʻoulu O2 (Fi O2) ≤300 mm Hg (1 mm Hg = 0.133 kPa).Inā hoʻokō ka mea maʻi i kekahi o kēia mau pae, ua koʻikoʻi ka maʻi: (a) ʻaʻole pono ka hanu ʻana e pono ai ka ea uila;(b) haʻalulu;(c) ʻino ʻē aʻe e pono ai ka mālama ʻana i loko o ka hale mālama kino (ICU).E like me nā mea i hōʻike ʻia ma luna nei, ua ʻike ʻia he 52 mau maʻi i ka maʻi koʻikoʻi i 2 mau hihia, maʻi koʻikoʻi i 5 mau hihia, a me ka maʻi haʻahaʻa i 45 mau hihia.
ʻO nā maʻi āpau, me nā maʻi maʻi haʻahaʻa, ʻeha a me nā maʻi koʻikoʻi, mālama ʻia e like me nā kaʻina hana maʻamau: (a) ʻO ka lāʻau adjuvant maʻamau;(b) Antiviral therapy: lopinavir/ritonavir a me α-interferon;(c) Hiki ke hoʻololi ʻia ke ʻano o ka lāʻau lapaʻau Kina kuʻuna e like me ke kūlana o ka mea maʻi.
Ua ʻae ʻia kēia haʻawina e ke Kōmike Review o ka Research Institute of Nanning Fourth Hospital a ua hoʻohana ʻia e hōʻiliʻili i ka ʻike maʻi.
Ka nānā 'ana i ka hematology o ke koko: hana 'ia ka nānā 'ana o ka hematology ma'amau ma luna o Mindray BC-6900 hematology analyzer (Mindray) a me Sysmex XN 9000 hematology analyzer (Sysmex).Ua hōʻiliʻili ʻia ke koko anticoagulant hoʻokēʻai ethylenediaminetetraacetic acid (EDTA) i ke kakahiaka ma hope o ka hoʻokomo ʻia ʻana o ka mea maʻi i ka haukapila.Ua hōʻoia ʻia ka loiloi kūlike ma waena o nā mea loiloi koko ʻelua ma luna e like me nā kaʻina hana hoʻomalu maikaʻi.Ma ka nānā ʻana i ka hematology, loaʻa ka helu keʻokeʻo keʻokeʻo (WBC) a me ka ʻokoʻa, ʻulaʻula ʻulaʻula (RBC) a me ka index i loaʻa pū me nā scatter plots a me nā histograms.
Flow cytometry o T lymphocyte subpopulations: BD (Becton, Dickinson and Company) FACSCalibur flow cytometer ua hoʻohana ʻia no ka hoʻoheheʻe cytometry kahe no ka nānā ʻana i nā subpopulations cell T.E noʻonoʻo i ka ʻikepili e ka polokalamu MultiSET.Ua hana ʻia ke ana e like me nā kaʻina hana maʻamau a me nā ʻōlelo a ka mea hana.E hoʻohana i kahi paipu hōʻiliʻili koko anticoagulated EDTA e hōʻiliʻili i 2 ml o ke koko venous.Hoʻohui mālie i ka hāpana ma ka hoʻohuli ʻana i ka pahu hāpana i kekahi mau manawa e pale i ka condensation.Ma hope o ka hōʻiliʻili ʻana o ka hāpana, hoʻouna ʻia ia i ka hale hana a nānā ʻia i loko o 6 mau hola ma ke ana wela.
Immunofluorescence kālailai: C-reactive protein (CRP) a me procalcitonin (PCT) ua kālailai koke ia ma hope o ka pau ana o ka anaana me ka hoʻohana koko laʻana ana e hematology, a kālailai ma ka FS-112 immunofluorescence ananaly (Wondfo Biotech Co., LTD.) ma. ka hoʻopili.) E hahai i nā ʻōlelo a ka mea hana a me nā kūlana kaʻina hana hoʻokolohua.
Nānā i ka serum alanine aminotransferase (ALT) a me ka aspartate aminotransferase (AST) ma ka HITACHI LABOSPECT008AS chemical analyzer (HITACHI).Ua nānā ʻia ka manawa prothrombin (PT) ma ka STAGO STA-R Evolution analyzer (Diagnostica Stago).
Reverse transcription quantitative polymerase chain reaction (RT-qPCR): E hoʻohana i ka RNA templates i hoʻokaʻawale ʻia mai nā swabs nasopharyngeal a i ʻole nā mea huna o ka hanu hanu haʻahaʻa e hana i ka RT-qPCR e ʻike iā SARS-CoV-2.Ua hoʻokaʻawale ʻia nā ʻakika nucleic ma ka SSNP-2000A nucleic acid i ka paepae hoʻokaʻawale ʻokoʻa (Bioperfectus Technologies).Ua hoʻolako ʻia ka pahu ʻike e Sun Yat-sen University Daan Gene Co., Ltd. a me Shanghai BioGerm Medical Biotechnology Co., Ltd. Ua hana ʻia ka pōʻai wela ma kahi ABI 7500 thermal cycler (Applied Biosystems).Ua wehewehe ʻia nā hopena hoʻāʻo viral nucleoside he maikaʻi a maikaʻi ʻole paha.
Ua hoʻohana ʻia ka polokalamu SPSS version 18.0 no ka ʻikepili ʻikepili;ho'āʻo paired-sample t-test, independent-sample t-test, a i ʻole Mann-Whitney U ho'āʻo, a ua manaʻo ʻia ka waiwai P <.05.
ʻElima mau maʻi maʻi koʻikoʻi a me ʻelua mau maʻi maʻi koʻikoʻi i ʻoi aku ka nui ma mua o ka poʻe i loko o ka hui haʻahaʻa (69.3 vs. 40.4).Hōʻike ʻia ka ʻike kikoʻī o nā maʻi maʻi koʻikoʻi 5 a me 2 maʻi koʻikoʻi ma ka Papa 1A a me B. ʻO nā maʻi maʻi koʻikoʻi a me nā maʻi koʻikoʻi he haʻahaʻa ma nā ʻāpana T cell a me nā helu lymphocyte āpau, akā ʻo ka helu keʻokeʻo keʻokeʻo he mea maʻamau, koe naʻe nā maʻi. me ke koko keʻokeʻo kiʻekiʻe (11.5 × 109/L).He kiʻekiʻe nō hoʻi nā neutrophils a me nā monocytes.He kiʻekiʻe ka helu PCT, ALT, AST a me PT o 2 mau maʻi maʻi koʻikoʻi a me 1 maʻi maʻi koʻikoʻi, a ua hoʻopili maikaʻi ʻia ka PT, ALT, AST o 1 maʻi maʻi koʻikoʻi a me 2 mau maʻi maʻi koʻikoʻi.Ma kahi kokoke i nā maʻi 7 he kiʻekiʻe CRP kiʻekiʻe.He haʻahaʻa nā Eosinophils (EOS) a me basophils (BASO) i nā maʻi maʻi koʻikoʻi a me nā maʻi koʻikoʻi (Papa 1A a me B).Hōʻike ka Papa 1 i ka wehewehe ʻana i ka laulā maʻamau o nā ʻāpana hematological i ka heluna kanaka makua Kina.
Ua hōʻike ʻia ka ʻikepili helu ma mua o ka mālama ʻana, CD3 +, CD4 +, CD8 + T cell, nā lymphocytes āpau, RBC mahele ākea (RDW), eosinophils a me basophils i haʻahaʻa loa ma mua o ka mālama ʻana (P = .000,. 000, .000, .012, . 04, .000 a me .001).ʻO nā hōʻailona inflammatory neutrophils, neutrophil/lymphocyte ratio (NLR) a me CRP ma mua o ka mālama ʻana ua ʻoi aku ka kiʻekiʻe ma mua o ka mālama ʻana (P = .004, .011 a me .017, kēlā me kēia).Ua emi nui ka Hb a me RBC ma hope o ka mālama ʻana (P = .032, .026).Ua hoʻonuiʻia ka PLT ma hope o ka mālamaʻana, akā,ʻaʻole ia he mea nui (P = .183) (Table 2).
ʻO nā subsets cell T (CD3 +, CD4 +, CD8 +), nā lymphocytes a me nā basophils o nā maʻi koʻikoʻi a me nā maʻi koʻikoʻi he haʻahaʻa loa ma mua o nā maʻi maʻamau (P = .025, 0.048, 0.027, 0.006 a me .046).ʻO nā kiʻekiʻe o nā neutrophils, NLR, PCT a me CRP i nā maʻi koʻikoʻi a me nā maʻi koʻikoʻi iʻoi aku ka kiʻekiʻe ma mua o nā maʻi maʻamau (P = .005, .002, .049 a me .002).ʻO nā maʻi koʻikoʻi a me nā maʻi koʻikoʻi he haʻahaʻa ka PLT ma mua o nā maʻi maʻamau;akā naʻe, ʻaʻole i koʻikoʻi ka ʻokoʻa (Papa 3).
ʻO ka CD3+, CD8+, nā lymphocytes a pau, nā platelets, a me nā basophils o nā maʻi ma luna o 50 mau makahiki he haʻahaʻa loa ia ma mua o ka poʻe maʻi ma lalo o 50 mau makahiki (P = .049, 0.018, 0.019, 0.010 a me .039, kēlā me kēia), 50 makahiki Ua ʻoi aku ka kiʻekiʻe o nā neutrophils, NLR ratio, CRP pae a me RDW ma mua o ka poʻe maʻi ma lalo o 50 mau makahiki (P = .0191, 0.015, 0.009, a me .010, kēlā me kēia) (Table 4).
Hoʻokumu ʻia ka COVID-19 e ka maʻi me ka coronavirus SARS-CoV-2, ka mea i ʻike mua ʻia ma Wuhan, Kina i Dekemaba 2019. Ua laha koke ka maʻi maʻi SARS-CoV-2 ma hope a alakaʻi i kahi maʻi maʻi honua.1-3 Ma muli o ka ʻike liʻiliʻi o ka maʻi maʻi a me ka pathology o ka maʻi maʻi, ʻoi aku ka nui o ka make ma ka hoʻomaka ʻana o ka maʻi maʻi.ʻOiai ʻaʻohe lāʻau antiviral, ua hoʻomaikaʻi maikaʻi ʻia ka mālama ʻana a me ka mālama ʻana o COVID-19.He ʻoiaʻiʻo loa kēia ma Kina ke hui pū ʻia nā lāʻau lapaʻau adjuvant me nā lāʻau lapaʻau Kina kuʻuna e mālama i nā hihia maʻamau.Ua pōmaikaʻi nā mea maʻi 26 COVID-19 mai ka ʻike maikaʻi ʻana i nā loli pathological a me nā ʻāpana ʻoihana o ka maʻi.maʻi maʻi.Mai ia manawa, ua emi ka nui o ka make.Ma kēia hōʻike, ʻaʻohe make ma waena o nā hihia he 52 i kālai ʻia, me 7 mau maʻi maʻi koʻikoʻi a maʻi koʻikoʻi (Table 1A a me B).
Ua ʻike ʻia ka nānā ʻana i nā maʻi i ka hapa nui o nā maʻi me COVID-19 i hōʻemi i nā lymphocytes a me nā subpopulations cell T, e pili ana i ka nui o ka maʻi.13, 27 I loko o kēia hōʻike, ua ʻike ʻia he haʻahaʻa haʻahaʻa loa nā CD3 +, CD4 +, CD8 + T, nā lymphocytes āpau, RDW ma mua o ka mālama ʻana, eosinophils a me basophils ma mua o ka mālama ʻana (P = .000, .000, .000, .012, .04, .000 a me .001).Ua like kā mākou hopena me nā hōʻike mua.He koʻikoʻi ko kēia mau hōʻike i ka nānā ʻana i ke koʻikoʻi o COVID-19.8, 13, 23-25, 27, ʻoiai ʻo nā hōʻailona inflammatory neutrophils, neutrophils/lymphocyte ratio (NLR) A me CRP ma hope o ka mālama ʻana ma mua o ka mālama ʻana (P = .004, . 011 a me .017), i ʻike ʻia a hōʻike mua ʻia i nā maʻi maʻi COVID-19.No laila, ua manaʻo ʻia kēia mau ʻāpana he mau hōʻailona pono no ka mālama ʻana i ka COVID-19.8.Ma hope o ka mālama ʻana, ua hoʻemi nui ʻia ka hemoglobin a me nā ʻulaʻula ʻulaʻula he 11 (P = .032, 0.026), e hōʻike ana he anemia ka mea maʻi i ka wā o ka mālama ʻana.Uaʻikeʻia ka piʻiʻana o ka PLT ma hope o ka mālamaʻana, akā,ʻaʻole ia he mea nui (P = .183) (Table 2).Ua manaʻo ʻia ka emi ʻana o nā lymphocytes a me T cell subpopulations e pili ana i ka pau ʻana o ka cell a me ka apoptosis i ka wā e hōʻiliʻili ai lākou i nā wahi inflammatory e hakakā ai i ka maʻi.A i ʻole, ua hoʻopau ʻia lākou e ka huna nui ʻana o nā cytokines a me nā protein inflammatory.8, 14, 27-30 Inā haʻahaʻa haʻahaʻa ka lymphocyte a me T cell subsets a kiʻekiʻe ka lakene CD4+/CD8+, ʻaʻole maikaʻi ka prognosis.29 I kā mākou nānā ʻana, ua hoʻihoʻi ʻia nā lymphocytes a me T cell subsets ma hope o ka mālama ʻana, a ua hoʻōla ʻia nā maʻi 52 a pau (Table 1).Uaʻikeʻia nā kiʻekiʻe o nā neutrophils, NLR, a me CRP ma mua o ka mālamaʻana, a laila ua emi nui ma hope o ka mālamaʻana (P = .004, .011, a me .017, i kēlā me kēia) (Table 2).Ua hōʻike mua ʻia ka hana o ka T cell subsets i ka maʻi a me ka pane ʻana o ka immune.29, 31-34
Ma muli o ka liʻiliʻi o ka nui o nā maʻi koʻikoʻi a me nā maʻi koʻikoʻi, ʻaʻole mākou i hana i ka helu helu helu ma nā ʻāpana ma waena o nā maʻi maʻi koʻikoʻi a me nā maʻi maʻi maʻi.ʻO nā subsets cell T (CD3+, CD4+, CD8+) a me nā lymphocytes a pau o nā maʻi koʻikoʻi a me nā maʻi koʻikoʻi ʻoi aku ka haʻahaʻa ma mua o ka poʻe maʻi haʻahaʻa.ʻO nā kiʻekiʻe o nā neutrophils, NLR, PCT, a me CRP i nā maʻi koʻikoʻi a me nā maʻi maʻi nui iʻoi aku ka kiʻekiʻe ma mua o ka poʻe maʻi maʻamau (P = .005, .002, .049, a me .002, i kēlā me kēia) (Table 3).Hoʻololi nā hoʻololi i nā ʻāpana hana i pili i ka paʻakikī o COVID-19.35.36 ʻAʻole maopopo ke kumu o ka basophilia;ma muli paha o ka ʻai ʻana i ka meaʻai i ka hakakā ʻana i ka maʻi maʻi ma ke kahua o ka maʻi e like me nā lymphocytes.35 Ua ʻike ʻia ka haʻawina ua hōʻemi pū ka poʻe maʻi me ka COVID-19 i nā eosinophils;14 Akā naʻe, ʻaʻole i hōʻike ʻia kā mākou ʻikepili e pili ana kēia ʻano ma muli o ka liʻiliʻi o nā hihia koʻikoʻi a koʻikoʻi i ʻike ʻia ma ke aʻo ʻana.
ʻO ka mea mahalo, ua ʻike mākou i nā maʻi maʻi koʻikoʻi a me ka maʻi koʻikoʻi, aia kahi pilina maikaʻi ma waena o nā waiwai PT, ALT, a me AST, e hōʻike ana i ka nui o ka pōʻino o ke kino i loaʻa i ka hoʻouka ʻana, e like me ka mea i ʻōlelo ʻia ma nā ʻike ʻē aʻe.37 No laila, he mau ʻāpana kūpono hou paha lākou no ka loiloi ʻana i ka pane a me ka wānana o ka mālama COVID-19.
Ua hōʻike hou ʻia ka hōʻike ʻana o ka CD3 +, CD8 +, nā lymphocytes āpau, nā platelets a me nā basophils o nā mea maʻi ma luna o 50 mau makahiki he haʻahaʻa loa ma mua o ka poʻe maʻi ma lalo o 50 makahiki (P = P = .049, .018, .019, .010 a me. 039, i kēlā me kēia), ʻoiai ke kiʻekiʻe o nā neutrophils, NLR, CRP, a me RBC RDW i nā maʻi ma luna o 50 mau makahiki i ʻoi aku ka kiʻekiʻe ma mua o nā mea maʻi ma lalo o 50 mau makahiki (P = .0191, 0.015, 0.009, a me .010. , pakahi) (Papa 4).Ua like kēia mau hopena me nā hōʻike mua.14, 28, 29, 38-41 ʻO ka emi ʻana o nā subpopulations cell T a me nā helu kiʻekiʻe CD4 + / CD8 + T pili i ka nui o ka maʻi;ʻoi aku ka paʻakikī o nā hihia ʻelemakule;No laila, ʻoi aku ka nui o nā lymphocytes e hoʻopau ʻia i ka pane ʻana a i ʻole ka pōʻino nui.Pēlā nō, ʻo kahi RBC RDW kiʻekiʻe e hōʻike ana ua hoʻomohala kēia mau maʻi i ka anemia.
Ua hōʻoia hou kā mākou mau noiʻi noiʻi he koʻikoʻi nui nā ʻāpana hematological no ka hoʻomaopopo maikaʻi ʻana i nā loli clinicopathological o nā mea maʻi COVID-19 a no ka hoʻomaikaʻi ʻana i ke alakaʻi o ka mālama ʻana a me ka wānana.
Ua hōʻiliʻili ʻo Liang Juanying lāua ʻo Nong Shaoyun i ka ʻikepili a me ka ʻike lapaʻau;Ua hana ʻo Jiang Liejun lāua ʻo Chi Xiaowei i ka ʻikepili ʻikepili;Ua hana ʻo Dewu Bi, Jun Cao, Lida Mo, a me Xiaolu Luo i ka nānā ʻana maʻamau;ʻO Huang Huayi ke kuleana o ka hāpai ʻana a me ke kākau ʻana.
E ʻoluʻolu e nānā i kāu leka uila no nā ʻōlelo aʻoaʻo no ka hoʻihoʻi ʻana i kāu ʻōlelo huna.Inā ʻaʻole i loaʻa iā ʻoe kahi leka uila i loko o 10 mau minuke, ʻaʻole i hoʻopaʻa inoa ʻia kāu leka uila a pono ʻoe e hana i kahi moʻokāki Wiley Online Library hou.
Inā pili ka helu wahi i kahi moʻokāki i loaʻa iā ʻoe, e loaʻa iā ʻoe kahi leka uila me nā kuhikuhi no ka hoʻihoʻi ʻana i ka inoa inoa
Ka manawa hoʻouna: Iulai-22-2021